Effect of Lopinavir/ritonavir protease inhibitor on the pharmacokinetics of Irinotecan in HIV-infected patients with advanced Kaposi’s sarcoma No significant financial relationships to disclose. This ...
Jasper Therapeutics Inc. has presented data at the AAAAI 2024 conference regarding its CD117-targeting antibody briquilimab and its potential use in allergy and CD117-triggered anaphylactic reactions.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback